Related Experiment Video

Updated: Jan 19, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.8K

Potent Activity of Composite Cyclin Dependent Kinase Inhibition against Hepatocellular Carcinoma

Yu-Yun Shao1,2,3, Yong-Shi Li4, Hung-Wei Hsu5

  • 1Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei 10051, Taiwan. yuyunshao@ntu.edu.tw.

Cancers
|September 29, 2019
PubMed

Insights

Dinaciclib effectively inhibited hepatocellular carcinoma (HCC) cell growth by targeting cell division kinases (CDKs). This CDK inhibitor showed significant anti-cancer activity in vitro and in vivo, with CDK9 inhibition appearing key.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Alterations in cell cycle regulators are hallmarks of hepatocellular carcinoma (HCC).
  • Cyclin-dependent kinases (CDKs) play critical roles in cell cycle progression and are frequently dysregulated in cancer.
  • Targeting multiple CDKs simultaneously offers a potential therapeutic strategy for HCC.

Purpose of the Study:

  • To evaluate the efficacy of dinaciclib, a composite inhibitor of CDKs 1, 2, 5, and 9, against hepatocellular carcinoma.
  • To investigate the mechanisms underlying dinaciclib's anti-cancer effects in HCC models.
  • To determine the relative contribution of individual CDK targets to dinaciclib's activity.

Main Methods:

  • In vitro studies using HCC cell lines to assess antiproliferative activity and target engagement.
  • Western blot analysis to evaluate the phosphorylation status of key cell cycle proteins (Rb, ATM, Pol II).
  • In vivo xenograft studies in mice to assess tumor growth inhibition and tolerability.
  • RNA interference (RNAi) and overexpression studies to elucidate the role of specific CDKs.

Main Results:

  • Dinaciclib demonstrated potent antiproliferative effects in HCC cell lines, irrespective of Rb or c-myc expression.
  • The drug effectively downregulated the phosphorylation of Rb, ATM, and RNA polymerase II, indicating inhibition of CDK targets.
  • In vivo studies showed significantly reduced tumor growth in mice treated with dinaciclib, with good tolerability.
  • RNAi targeting CDK1 and CDK9 was more effective than targeting CDK2 or CDK5; CDK9 inhibition was identified as a crucial mechanism.

Conclusions:

  • Composite inhibition of CDKs 1, 2, 5, and 9 by dinaciclib exhibits significant in vitro and in vivo efficacy against hepatocellular carcinoma.
  • Dinaciclib represents a promising therapeutic agent for HCC, warranting further clinical investigation.
  • CDK9 inhibition appears to be the primary driver of dinaciclib's anti-cancer activity in HCC.
Keywords:
cell cyclecyclin-dependent kinasedinaciclibhepatocellular carcinoma

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.4K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

6.0K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.6K
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
3.3K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
6.5K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.3K